论文部分内容阅读
The Food and Drug Administration(FDA)has approved two mechanism-based treatments for tuberous sclerosis complex(TSC)-everolimus and vigabatrin.However,these treatments have not been systematically studied in individuals with TSC and severe autism.The aim